Status:
COMPLETED
A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This 2 arm open-label study will assess the safety and tolerability of combination treatment with Peginterferon alfa (Pegasys) and Ribavirin (Copegus) in patients with chronic hepatitis C. Patients wi...
Eligibility Criteria
Inclusion
- adult patients \>/= 18 years of age
- serologic evidence of chronic hepatitis C infection
- compensated liver disease
- negative pregnancy test and in both males and females use of 2 forms of contraception during study and 6 months after treatment
Exclusion
- history or other evidence of a medical condition associated with chronic liver disease other than HCV
- hepatitis A, hepatitis B or HIV infection
- hepatocellular carcinoma
- severe concomitant disease
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
2695 Patients enrolled
Trial Details
Trial ID
NCT00940420
Start Date
October 1 2002
End Date
November 1 2009
Last Update
November 2 2016
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Afula, Israel, 18101
2
Ashkelon, Israel, 78278
3
Bat Yam, Israel
4
Beersheba, Israel, 84105